CO5070670A1 - Taloproteinasas de arilsulfonamidas y estatinas - Google Patents

Taloproteinasas de arilsulfonamidas y estatinas

Info

Publication number
CO5070670A1
CO5070670A1 CO99016109A CO99016109A CO5070670A1 CO 5070670 A1 CO5070670 A1 CO 5070670A1 CO 99016109 A CO99016109 A CO 99016109A CO 99016109 A CO99016109 A CO 99016109A CO 5070670 A1 CO5070670 A1 CO 5070670A1
Authority
CO
Colombia
Prior art keywords
statin
taloproteinases
arilsulphonamid
pharmaceutically acceptable
salt
Prior art date
Application number
CO99016109A
Other languages
English (en)
Inventor
Roger Schofield Newton
Bruce David Roth
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5070670A1 publication Critical patent/CO5070670A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica CARACTERIZADA porque comprende:a.- Una cantidad de un inhibidor de MMP o una sal de adición ácida farmacéuticamente aceptable de él;b.- Una cantidad de una estatina o una sal farmacéuticamente aceptable de ella; yc.- Un protector o diluyente farmacéuticamente aceptable.
CO99016109A 1998-03-17 1999-03-16 Taloproteinasas de arilsulfonamidas y estatinas CO5070670A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
CO5070670A1 true CO5070670A1 (es) 2001-08-28

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99016109A CO5070670A1 (es) 1998-03-17 1999-03-16 Taloproteinasas de arilsulfonamidas y estatinas

Country Status (18)

Country Link
EP (1) EP1063991A1 (es)
JP (1) JP2002506818A (es)
KR (1) KR20010041916A (es)
AR (1) AR018113A1 (es)
AU (1) AU1591699A (es)
BR (1) BR9815745A (es)
CA (1) CA2309588A1 (es)
CO (1) CO5070670A1 (es)
GT (1) GT199900039A (es)
HN (1) HN1999000029A (es)
MY (1) MY140504A (es)
NZ (1) NZ505994A (es)
PA (1) PA8469001A1 (es)
PE (1) PE20000348A1 (es)
SV (1) SV1999000026A (es)
UY (1) UY25436A1 (es)
WO (1) WO1999047138A1 (es)
ZA (1) ZA992106B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
RU2410118C2 (ru) 2004-12-15 2011-01-27 Зольвай Фармасьютиклз Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611410A (pt) * 1995-11-02 1999-01-05 Warner Lambert Co Método e composição farmacêutica para regular a concentração de lipídios
PL186416B1 (pl) * 1996-05-17 2004-01-30 Warner Lambert Co Związek bifenylosulfonamidowy i preparat farmaceutyczny zawierający ten związek
IL128545A0 (en) * 1996-12-09 2000-01-31 Warner Lambert Co Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
PA8469001A1 (es) 2002-09-17
AU1591699A (en) 1999-10-11
CA2309588A1 (en) 1999-09-23
BR9815745A (pt) 2000-11-14
NZ505994A (en) 2003-10-31
JP2002506818A (ja) 2002-03-05
SV1999000026A (es) 2000-01-18
UY25436A1 (es) 2001-10-25
GT199900039A (es) 2000-09-06
HN1999000029A (es) 1999-09-29
KR20010041916A (ko) 2001-05-25
ZA992106B (en) 1999-09-30
MY140504A (en) 2009-12-31
AR018113A1 (es) 2001-10-31
WO1999047138A1 (en) 1999-09-23
EP1063991A1 (en) 2001-01-03
PE20000348A1 (es) 2000-05-22

Similar Documents

Publication Publication Date Title
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
DE69434214D1 (de) HIV protease inhibitoren
GR3030719T3 (en) Sulfonamide inhibitors of hiv-aspartyl protease.
HUP0102250A3 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
EA199900373A2 (ru) Фармацевтические композиции
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
NO981938D0 (no) Proteaseinhibitorer
NO990548L (no) Inhibitorer for cystein-protease
HUP0103283A3 (en) Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds
BG103425A (en) Pharmaceutical composition
FI925615A (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en HMG-CoA-reduktas-inhibitorfoerening
TR200200129T2 (tr) Hepatit C inhibitörü tri-peptidler
PT1193270E (pt) Pirrolobenzodiazepinas
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
NO996352D0 (no) <Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus
PH31249A (en) Inhibitors of hiv protease.
IT1298163B1 (it) Inibitori di solfammido-metalloproteasi
NO20005196D0 (no) Substituerte pyrrolidinhydroksamat-metallproteaseinhibitorer
EA199800023A1 (ru) Фармацевтическая композиция, содержащая ингибитор протеиназы и моноглицерид
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
NO934721D0 (no) Hemmere av HIV-protease som er nyttige for behandling av AIDS
CO5070670A1 (es) Taloproteinasas de arilsulfonamidas y estatinas
EE200000568A (et) HIV-proteaasi inhibiitorite valmistamismeetod
IT1289238B1 (it) Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina
EP0785786A4 (en) MICROBIAL SYNTHESIS OF HIV PROTEASE INHIBITORS